Press release
AL Amyloidosis Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Janssen Pharma, Prothena, Alexion Pharma, Alnylam Pharma, Attralus, Neurimmune AG
DelveInsight's "AL Amyloidosis Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the AL Amyloidosis, historical and forecasted epidemiology as well as the AL Amyloidosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the AL Amyloidosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; AL Amyloidosis Market Forecast [https://www.delveinsight.com/sample-request/al-amyloidosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key facts of the AL Amyloidosis Market Report:
*
The AL Amyloidosis market size was valued approximately USD 920 Million in the year 2021 and is anticipated to grow with a significant CAGR during the study period (2020-2033)
*
AL amyloidosis is a rare disease, translating to ~8,500 new cases per year in the 7MM. This disease presents in older adults, median age 64, with slight male predominance (54%). According to the Amyloidosis Foundation, AL amyloidosis is the most common type, with approximately 4,500 new cases diagnosed every year in the United States
*
In 2021, the total incident cases of AL Amyloidosis were the highest in the US, with nearly 4,500 cases, and the lowest in Spain with approximately 400 cases
*
The epidemiology of AL Amyloidosis was divided based on total incidence, gender-specific cases, and age-specific cases. In 2021, Japan accounted for more than 500 incident cases for AL Amyloidosis
*
Among EU5 countries, Germany had the highest number of incident cases of AL Amyloidosis (>900 cases) in 2021
*
Key AL Amyloidosis Companies: Janssen Pharmaceuticals, Prothena, Alexion Pharmaceuticals, Alnylam Pharmaceuticals, Attralus, Neurimmue AG, Sorrento Therapeutics, Zentalis Pharmaceuticals, Sanofi, Astellas Pharma GmbH, GlaxoSmithKline, Takeda Oncology, and others
*
Key AL Amyloidosis Therapies: Daratumumab, Birtamimab, CAEL-101, Vutrisiran, AT-03, NI006, STI-6129, ZN d5, Isatuximab, Bendamustine, Belantamab mafodotin, xazomib, and others
*
The AL Amyloidosis epidemiology based on gender analyzed that there are slightly more cases in males than females in the United States
*
The AL Amyloidosis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage AL Amyloidosis pipeline products will significantly revolutionize the AL Amyloidosis market dynamics.
AL Amyloidosis Overview
AL amyloidosis, also known as primary amyloidosis, is a rare and serious disease caused by the abnormal deposition of amyloid proteins in various tissues and organs. The "AL" stands for "amyloid light chain," which refers to the type of protein involved.
Get a Free sample for the AL Amyloidosis Market Report:
https://www.delveinsight.com/report-store/al-amyloidosis-market [https://www.delveinsight.com/report-store/al-amyloidosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
AL Amyloidosis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
AL Amyloidosis Epidemiology Segmentation:
The AL Amyloidosis market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
*
Total Prevalence of AL Amyloidosis
*
Prevalent Cases of AL Amyloidosis by severity
*
Gender-specific Prevalence of AL Amyloidosis
*
Diagnosed Cases of Episodic and Chronic AL Amyloidosis
Download the report to understand which factors are driving AL Amyloidosis epidemiology trends @ AL Amyloidosis Epidemiology Forecast [https://www.delveinsight.com/sample-request/al-amyloidosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
AL Amyloidosis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the AL Amyloidosis market or expected to get launched during the study period. The analysis covers AL Amyloidosis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the AL Amyloidosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
AL Amyloidosis Therapies and Key Companies
*
Daratumumab: Janssen Pharmaceuticals
*
Birtamimab: Prothena
*
CAEL-101: Alexion Pharmaceuticals
*
Vutrisiran: Alnylam Pharmaceuticals
*
AT-03: Attralus
*
NI006: Neurimmue AG
*
STI-6129: Sorrento Therapeutics
*
ZN d5: Zentalis Pharmaceuticals
*
Isatuximab: Sanofi
*
Bendamustine: Astellas Pharma GmbH
*
Belantamab mafodotin: GlaxoSmithKline
*
xazomib: Takeda Oncology
Discover more about therapies set to grab major AL Amyloidosis market share @ AL Amyloidosis Treatment Market [https://www.delveinsight.com/sample-request/al-amyloidosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
AL Amyloidosis Market Strengths
*
Recent launch of approved therapies and robust pipeline of innovative, first-in-class therapies are likely to boost AL amyloidosis market
*
Improved awareness in recent years is leading to increasing disease incidence
*
Collaboration between major market players (Commercialization of Darzalex Faspro by Genmab and Janssen Biotech, acquisition of Caelum biosciences by AstraZeneca in 2021) is expected to drive market growth
AL Amyloidosis Market Opportunities
*
The friendly regulatory policies with orphan drug benefit, limited competition, high disease burden, are glittering opportunities for upcoming market players
*
Drugs that can offer survival benefits for high-risk patients with good
*
QALYs remains largely an unmet need
*
The treatment of newly diagnosed AL in the future will likely include daratumumab-based therapy in conjunction with fibril-directed therapy which targets the amyloid protein already deposited in the heart. Their combination has the potential to improve outcomes in future
Scope of the AL Amyloidosis Market Report
*
Study Period: 2020-2034
*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
*
Key AL Amyloidosis Companies: Janssen Pharmaceuticals, Prothena, Alexion Pharmaceuticals, Alnylam Pharmaceuticals, Attralus, Neurimmue AG, Sorrento Therapeutics, Zentalis Pharmaceuticals, Sanofi, Astellas Pharma GmbH, GlaxoSmithKline, Takeda Oncology, and others
*
Key AL Amyloidosis Therapies: Daratumumab, Birtamimab, CAEL-101, Vutrisiran, AT-03, NI006, STI-6129, ZN d5, Isatuximab, Bendamustine, Belantamab mafodotin, xazomib, and others
*
AL Amyloidosis Therapeutic Assessment: AL Amyloidosis current marketed and AL Amyloidosis emerging therapies
*
AL Amyloidosis Market Dynamics: AL Amyloidosis market drivers and AL Amyloidosis market barriers
*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
*
AL Amyloidosis Unmet Needs, KOL's views, Analyst's views, AL Amyloidosis Market Access and Reimbursement
To know more about AL Amyloidosis companies working in the treatment market, visit @ AL Amyloidosis Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/al-amyloidosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. AL Amyloidosis Market Report Introduction
2. Executive Summary for AL Amyloidosis
3. SWOT analysis of AL Amyloidosis
4. AL Amyloidosis Patient Share (%) Overview at a Glance
5. AL Amyloidosis Market Overview at a Glance
6. AL Amyloidosis Disease Background and Overview
7. AL Amyloidosis Epidemiology and Patient Population
8. Country-Specific Patient Population of AL Amyloidosis
9. AL Amyloidosis Current Treatment and Medical Practices
10. AL Amyloidosis Unmet Needs
11. AL Amyloidosis Emerging Therapies
12. AL Amyloidosis Market Outlook
13. Country-Wise AL Amyloidosis Market Analysis (2020-2034)
14. AL Amyloidosis Market Access and Reimbursement of Therapies
15. AL Amyloidosis Market Drivers
16. AL Amyloidosis Market Barriers
17. AL Amyloidosis Appendix
18. AL Amyloidosis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=al-amyloidosis-market-to-show-remarkable-growth-trends-from-2024-to-2034-delveinsight-reports-janssen-pharma-prothena-alexion-pharma-alnylam-pharma-attralus-neurimmune-ag]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release AL Amyloidosis Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Janssen Pharma, Prothena, Alexion Pharma, Alnylam Pharma, Attralus, Neurimmune AG here
News-ID: 3776749 • Views: …
More Releases from ABNewswire
Denver's Best Appliance Repair Responds to Rising Demand for Emergency Appliance …
Denver's Best Appliance Repair expands emergency services across the Denver metro with same-day repairs, 7-day availability, 5-year parts warranty, and professional licensed technicians serving residential and commercial clients.
Household appliance failures don't follow a schedule. When a refrigerator stops cooling in the middle of summer or a washing machine floods a basement on a Sunday evening, families need immediate help. Denver's Best Appliance Repair has responded to this growing need by…
Oak Hill Clinic Reaches 30,000 Client Milestone with Results-Driven Deep Tissue …
Deep Relief in Oak Hill, Austin, has served 30,000 clients through specialized massage, chiropractic, and acupuncture care. The clinic accepts insurance and focuses on results-driven treatments for pain relief.
Deep Relief, an Oak Hill-based wellness clinic, has achieved a significant milestone by serving more than 30,000 clients seeking Relief from chronic pain, muscle tension, and mobility issues. The clinic's success stems from its commitment to advanced, results-focused bodywork that goes beyond…
Vertex Fleet Expands Nationwide Network to Combat Growing Trailer Drop Yard Shor …
Vertex Fleet announces major expansion of secure parking facilities nationwide, addressing the critical shortage of commercial vehicle storage with 15+ new locations featuring 24/7 security and technology-driven access.
The freight and logistics industry faces a mounting crisis as demand for secure parking spaces continues to outpace supply across the United States. Vertex Fleet [https://www.vertexfleet.com/], a leading provider of industrial outdoor storage solutions, has announced significant expansion plans to address this critical…
HVAC in Denver Sees Service Enhancement as Denver's Best Heating and AC Repair L …
Denver's Best Heating and AC Repair expands 24/7 emergency services across 23 metro cities, offering A+ rated heating, cooling, and commercial HVAC solutions with rapid response times and multi-brand expertise.
Denver's Best Heating and AC Repair [https://www.denversbestheatingandacrepair.com/]has expanded its service capabilities to meet growing demand for reliable heating and cooling solutions across the Denver Metro area. The A+ rated contractor now provides 24/7 emergency response services to 23 cities, addressing critical…
More Releases for Amyloidosis
Amyloidosis Market Massive Growth opportunity Ahead
Introduction
Amyloidosis is a rare, progressive disease characterized by the abnormal deposition of amyloid proteins in tissues and organs, leading to organ dysfunction and, in severe cases, life-threatening complications. The condition can affect the kidneys, heart, liver, and nervous system, making early detection and effective treatment essential. Historically underdiagnosed, amyloidosis is now gaining visibility due to advances in diagnostic tools, imaging technologies, and therapeutic innovations.
In 2024, the global Amyloidosis Market is…
Evolving Market Trends In The Transthyretin Amyloidosis Treatment Industry: Inno …
The Transthyretin Amyloidosis Treatment Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Transthyretin Amyloidosis Treatment Market Size During the Forecast Period?
The market for transthyretin amyloidosis treatments has witnessed significant growth in the past few years. The market, which was valued at…
What's Driving the Transthyretin Amyloidosis Treatment Market 2025-2034: Increas …
What Are the Projections for the Size and Growth Rate of the Transthyretin Amyloidosis Treatment Market?
The market for transthyretin amyloidosis treatment has seen robust growth in the past years. Its size is forecasted to increase from $5.52 billion in 2024 to $5.95 billion in 2025, with a compound annual growth rate (CAGR) of 7.8%. The surge in the market over the historic period is due to increased disease awareness, progress…
Unveiling Transthyretin Amyloidosis Treatment Market 2024
The transthyretin amyloidosis treatment market size has grown strongly in recent years. It will grow from $5.07 billion in 2023 to $5.52 billion in 2024 at a compound annual growth rate (CAGR) of 8.9%. The growth in the historic period can be attributed to increased disease awareness, advancements in diagnostic tools, drug development and approvals, patient advocacy and support, collaboration in research..
The transthyretin amyloidosis treatment market size is…
AL Amyloidosis Therapeutics Market - Transforming the landscape of AL amyloidosi …
Newark, New Castle, USA: The "AL Amyloidosis Therapeutics Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
AL Amyloidosis Therapeutics Market: https://www.growthplusreports.com/report/al-amyloidosis-therapeutics-market/8684
This latest report researches the industry structure,…
Transthyretin Amyloidosis (ATTR) Market 2022 | Detailed Report
The top-notch information research report published by markets and markets is a vital asset that offers qualitative and quantitative factors of the Transthyretin Amyloidosis (ATTR) market. The research study and methodologies mentioned in the report examine the critical vendors by considering their contribution to the global market. Furthermore, the report offers an in-depth insight into leading players’ performance based on revenue generation and client requirements. Also, the research report reveals…
